[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![OzmosiHealth Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1055982930.png) Ozmosi [@OzmosiHealth](/creator/twitter/OzmosiHealth) on x 2633 followers
Created: 2025-07-23 20:02:34 UTC

Hillhurst Biopharmaceuticals administers first dose in Phase 2a trial for HBI-002, a new treatment for Sickle Cell Disease.

More Info: $XBI $IBB $XPH $PPH

![](https://pbs.twimg.com/media/GwkVGP7agAAdNKx.jpg)

XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1948111515078504861/c:line.svg)

**Related Topics**
[$pph](/topic/$pph)
[$xph](/topic/$xph)
[$ibb](/topic/$ibb)
[$xbi](/topic/$xbi)
[more info](/topic/more-info)

[Post Link](https://x.com/OzmosiHealth/status/1948111515078504861)